Investors seem to focus more on the company's revenue growth despite the decrease in earnings per share. The company's long-term track record of an annual TSR of 20% over five years makes it a business worth watching.
Investors may be expecting a turnaround in the company's lackluster revenue performance, hence the moderate P/S ratio. However, the company's muted revenue growth estimates compared to the industry make its current P/S ratio unexpected. A positive change is needed to justify this ratio.
Prestige Consumer Healthcare's revenue growth is predicted to slow, with an estimated annual growth rate of 1.9% until 2025, significantly below the historical 4.2% p.a. growth. Compared to industry peers forecasted to grow at 9.0% per year, Prestige is expected to lag behind.
An insider selling shares below the current price may suggest they deemed the lower price fair, questioning their view of the recent higher valuation. However, this is a weak sign as it doesn't imply insiders think the shares are fully valued. The level of insider ownership indicates a reasonable alignment with shareholder interests.
Gainers: •$バイオヘブン(BHVN.US)$+70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven) •$ブルーム(VRM.US)$+33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO) •$ヌービー・ホールディング(NVVE.US)$+10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets) •$ショックウェーブ・メディカル(SWAV.US)$+14.6% (I...
プレステージ・コンシューマー・ヘルスケアに関するコメント
コラムToday's pre-market stock movers: PTON, NVAX, AMC, SONY and more
• $バイオヘブン(BHVN.US)$ +70.3% (Biohaven Pharmaceutical and Pfizer (PFE) announce that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven)
• $ブルーム(VRM.US)$ +33.3% (also CEO Paul Hennessy steps down; Tom Shortt appointed as CEO)
• $ヌービー・ホールディング(NVVE.US)$ +10.2% (NVVE and CENN announce alliance to offer electrification solution for commercial fleets)
• $ショックウェーブ・メディカル(SWAV.US)$ +14.6% (I...
コラムTop upgrades and downgrades on 5/10
•$オートリブ(ALV.US)$ : UBS Upgrades to Buy from Neutral - PT $90 (from $103)
• $クリーンエナジーフューエルズ(CLNE.US)$ : Raymond James Upgrades to Outperform from Market Perform - PT $6
• $EOGリソーシズ(EOG.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $170
• $ジェニュイン・パーツ(GPC.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $133
• $グラフィック・パッケージング・ホールディング(GPK.US)$ : Exane Upgrades to Outperform from Neutral - PT $26
• $ヘルスケア・トラスト・オブ・アメリカ(HTA.US)$ : Berenbe...
コラムTop upgrades and downgrades on 5/9
• $シグナ・グループ(CI.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $329 (from $242)
• $ディーローカル(DLO.US)$ : New Street Research Upgrades to Buy from Neutral - PT $38
• $グッドイヤー・タイヤ・アンド・ラバー(GT.US)$ : CFRA Upgrades to Buy from Hold - PT $20 (from $24)
• $マッチ・グループ・インク(MTCH.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $115 (from $140)
• $プレステージ・コンシューマー・ヘルスケア(PBH.US)$ : Oppenheimer Upgrades to Outperform from Perform - P...
コラムTop upgrades and downgrades on 3/25
• $Farfetch(FTCH.US)$: Societe Generale Upgrades to Buy from Hold - PT $22
• $テバ・ファーマスーティカル・インダストリーズ(TEVA.US)$ : Bernstein Upgrades to Outperform from Market Perform - PT $11
Downgrades
• $ASMLホールディング(ASML.US)$ : Redburn Downgrades to Sell from Neutral
• $AutoWeb(AUTO.US)$ : Lake Street Capital Markets Downgrades to Hold from Buy - PT $2.50
• $アクサルタ・コーティング・システムズ(AXTA.US)$ : RBC Capital Downgrades to Sector Perform from Outperform - PT $...
まだコメントはありません